/
Oncology
Lung Cancer
732
Pipeline Programs↗
1.4K
Active Trials↗
359
Companies Involved↗
Lung Cancer is a highly competitive landscape with 732 programs across 359 companies. The most active players are Johnson & Johnson, GSK, Minghui Pharmaceutical (Hangzhou) Ltd. 195 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical157
Phase 1104
Phase 2276
Phase 3195
Approved
No programs
Analysis
Modality Breakdown
83%
Small molecule
547 of 657 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 657 classified programs, each share of the total. Modality classified for 95% of 732 pipeline programs.
Analysis
Trial Status
4,747
clinical trials
Completed1,890 · 40%
Recruiting730 · 15%
Unknown status628 · 13%
Terminated604 · 13%
Active, not recruiting388 · 8%
Not yet recruiting289 · 6%
Other218 · 5%
Clinical Trials
Trial Activity
4747 trials
Page 1 of 317
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)